# Shin Poong Pharmaceutical Co. Ltd. trials: 27 (2026)

ClinicalTrials.gov lists 27 trials with Shin Poong Pharmaceutical Co. Ltd. as lead sponsor, 2 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Shin Poong Pharmaceutical Co. Ltd.: 27 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/shin-poong-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 27
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 27, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 14, 2025 | NCT07064525 | Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension | Shin Poong Pharmaceutical Co. Ltd. | Phase 2 | Enrolling by invitation | Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure, Diabete Mellitus | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07064525) |
| February 14, 2025 | NCT06826872 | Efficacy and Safety of SPC1001 in Patients With Essential Hypertension | Shin Poong Pharmaceutical Co. Ltd. | Phase 2 | Recruiting | Hypertension, Essential, Cardiovascular Diseases, Cardiology | 252 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06826872) |
| October 28, 2024 | NCT06660719 | Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care | Shin Poong Pharmaceutical Co. Ltd. | Phase 3 | Recruiting | Ischemic Stroke | 852 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06660719) |
| May 3, 2024 | NCT06399042 | Pivotal Study to Evaluate Efficacy and Safety of SP5M002 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee... | Shin Poong Pharmaceutical Co. Ltd. | Phase 3 | Unknown | Osteoarthritis | 297 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06399042) |
| March 13, 2024 | NCT06307847 | Pivotal Study to Evaluate Efficacy and Safety of SP5M001 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee... | Shin Poong Pharmaceutical Co. Ltd. | Phase 3 | Completed | Osteoarthritis Thumb | 223 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06307847) |
| January 26, 2024 | NCT06225635 | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Ezerosu Tab | Shin Poong Pharmaceutical Co. Ltd. | Phase 1 | Completed | Hyperlipidemias | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06225635) |
| January 19, 2024 | NCT06212648 | Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension | Shin Poong Pharmaceutical Co. Ltd. | Phase 2 | Completed | Hypertension, Essential Hypertension | 253 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06212648) |
| December 1, 2022 | NCT05633420 | Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients | Shin Poong Pharmaceutical Co. Ltd. | Phase 2 | Completed | COVID-19 | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05633420) |
| October 10, 2022 | NCT05574166 | A Phase I Study to Evaluate Safety and Pharmacokinetics of Escalating Single Doses and Multiple Doses of SP-8356 | Shin Poong Pharmaceutical Co. Ltd. | Phase 1 | Terminated | Atherosclerosis, Ischemic Stroke | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05574166) |
| October 20, 2021 | NCT05084911 | The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3) | Shin Poong Pharmaceutical Co. Ltd. | Phase 3 | Completed | COVID-19 | 1,807 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05084911) |
| September 27, 2021 | NCT05058027 | Anti-adhesive Effect and Safety of MEDICURTAIN Applied to Undergoing Thyroid Surgery (Pivotal Study) | Shin Poong Pharmaceutical Co. Ltd. | Not applicable | Completed | Tissue Adhesion, Surgery-Induced | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05058027) |
| September 20, 2021 | NCT05049434 | Efficacy and Safety for Medicurtain® in Prevention of Adhesion After Endoscopic Sinus Surgery (Pivotal Study) | Shin Poong Pharmaceutical Co. Ltd. | Not applicable | Completed | Sinusitis, Tissue Adhesion, Surgery-Induced | 77 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05049434) |
| February 25, 2021 | NCT04770194 | Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SP-8008 | Shin Poong Pharmaceutical Co. Ltd. | Phase 1 | Completed | Acute Coronary Syndrome, Stroke | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04770194) |
| January 8, 2021 | NCT04701606 | The Safety and Efficacy of Pyronaridine-artesunate (Pyramax® or Artecom®)in COVID-19 Patients | Shin Poong Pharmaceutical Co. Ltd. | Phase 2/3 | Unknown | Covid19 | 402 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04701606) |
| December 29, 2020 | NCT04688281 | Spine Surgery for Adhesions in Patients Evaluated for Efficacy and Safety of MedicurtainⓇ (Pivotal Study) | Shin Poong Pharmaceutical Co. Ltd. | Not applicable | Completed | Intervertebral Disc Disorder, Thoracic Intervertebral Disc Disorders, Thoracolumbar Intervertebral Disc Disorders... | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04688281) |
| December 17, 2020 | NCT04672421 | The Efficacy and Safety of Medicurtain® in Patients With Total Laparoscopic Hysterectomy (Pivotal Study) | Shin Poong Pharmaceutical Co. Ltd. | Not applicable | Completed | Laparoscopy, Tissue Adhesion, Surgery-Induced, Leiomyoma of the Uterine Body | 107 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04672421) |
| November 20, 2020 | NCT04638855 | The Efficacy and Safety of Medicurtain® in Patients With Hysteroscopy (Pivotal Study) | Shin Poong Pharmaceutical Co. Ltd. | Not applicable | Completed | Intrauterine Synechiae, Tissue Adhesion, Surgery-Induced | 223 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04638855) |
| August 31, 2020 | NCT04532931 | Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 | Shin Poong Pharmaceutical Co. Ltd. | Phase 2 | Completed | COVID-19 | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04532931) |
| July 21, 2020 | NCT04479449 | Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA | Shin Poong Pharmaceutical Co. Ltd. | Phase 2 | Completed | Ischemic Stroke | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04479449) |
| July 17, 2020 | NCT04475107 | The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients | Shin Poong Pharmaceutical Co. Ltd. | Phase 2 | Completed | COVID-19 | 113 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04475107) |
| January 24, 2019 | NCT03814616 | Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections | Shin Poong Pharmaceutical Co. Ltd. | Phase 2 | Unknown | Malaria,Falciparum | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03814616) |
| September 19, 2017 | NCT03288038 | The Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary... | Shin Poong Pharmaceutical Co. Ltd. | Phase 3 | Completed | Hypercholesterolemia | 382 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03288038) |
| June 28, 2017 | NCT03201770 | Cohort Event Monitoring Study of Pyramax® | Shin Poong Pharmaceutical Co. Ltd. | Phase 4 | Completed | Malaria,Falciparum | 8,572 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03201770) |
| October 26, 2016 | NCT02944734 | Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With... | Shin Poong Pharmaceutical Co. Ltd. | Phase 2 | Completed | Essential Hypertension | 392 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02944734) |
| June 1, 2016 | NCT02787278 | Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPA | Shin Poong Pharmaceutical Co. Ltd. | Phase 2 | Completed | Ischemic Stroke | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02787278) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 2 | 10 |
| Phase 2/3 | 1 |
| Phase 3 | 5 |
| Phase 4 | 1 |
| Not applicable | 5 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 20 |
| Unknown | 3 |
| Recruiting | 2 |
| Terminated | 1 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Tissue Adhesions | 5 |
| Ischemic Stroke | 5 |
| COVID-19 | 5 |
| Essential Hypertension | 3 |
| Hypertension | 3 |
| Malaria, Falciparum | 2 |
| Osteoarthritis, Knee | 2 |
| Cardiovascular Diseases | 2 |
| Stroke | 2 |
| Intervertebral disc disease | 1 |
| Hyperlipidemias | 1 |
| Arteriosclerosis | 1 |
| Intracranial Hemorrhages | 1 |
| Osteoarthritis | 1 |
| Gynatresia | 1 |
| Hypercholesterolemia | 1 |
| Atherosclerosis | 1 |
| Acute Coronary Syndrome | 1 |
| Diabetes Mellitus | 1 |
| Myofibroma | 1 |
| Sinusitis | 1 |
| Vascular Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Prosthodontics practices in the United States](https://specstream.ai/data/businesses/prosthodontics-practices/united-states)
- [Private equity firms in the United States](https://specstream.ai/data/businesses/private-equity-firms/united-states)
- [Polynesian restaurants in the United States](https://specstream.ai/data/businesses/polynesian-restaurants/united-states)
- [Pizza restaurants in the United States](https://specstream.ai/data/businesses/pizza-restaurants/united-states)
- [Pediatric pulmonology practices in the United States](https://specstream.ai/data/businesses/pediatric-pulmonology-practices/united-states)
